Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
Abstract Background Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted by C26 colon carcinoma cells was respons...
Saved in:
Main Authors: | Susan C. Kandarian (Author), Rachel L. Nosacka (Author), Andrea E. Delitto (Author), Andrew R. Judge (Author), Sarah M. Judge (Author), John D. Ganey (Author), Jesse D. Moreira (Author), Robert W. Jackman (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2018-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle
by: Rachel L. Nosacka, et al.
Published: (2020) -
R‐ketorolac ameliorates cancer‐associated cachexia and prolongs survival of tumour‐bearing mice
by: Sophia E. Chrysostomou, et al.
Published: (2024) -
Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour‐bearing mice
by: Isabelle S. Massart, et al.
Published: (2024) -
Extramedullary Myeloid Cell Tumour Presenting As Leukaemia Cutis
by: Thappa Devinder Mohan, et al.
Published: (2002) -
Ganoderma triterpenoids attenuate tumour angiogenesis in lung cancer tumour-bearing nude mice
by: Wei Liu, et al.
Published: (2020)